Protective effects of ethyl gallate and pentagalloylglucose, the active components of Qingwen Baidu Decoction, against lipopolysaccharide-induced acute lung injury in rats.
Acute Lung Injury
/ chemically induced
Animals
Capillary Permeability
/ drug effects
Disease Models, Animal
Drugs, Chinese Herbal
/ pharmacology
Gallic Acid
/ analogs & derivatives
Hydrolyzable Tannins
/ pharmacology
Lipopolysaccharides
Lung
/ drug effects
Male
Neutrophil Infiltration
/ drug effects
Pulmonary Edema
/ chemically induced
Rats, Sprague-Dawley
Qingwen Baidu Decoction
acute lung injury
ethyl gallate
pentagalloylglucose
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
23
4
2019
Statut:
epublish
Résumé
The aim of this study was to investigate the bioactive constituents of Qingwen Baidu Decoction (QBD) in a rat model of acute lung injury (ALI) induced by lipopolysaccharide (LPS). Our previous studies showed that ethyl gallate (EG) and pentagalloylglucose (PGG) were the active components of QBD for the treatment of ALI. We isolated two compounds and identified the structures of them by nuclear magnetic resonance and mass spectrometer. Lung injury was induced by intratracheal instillation with LPS (5 mg/kg). Rats were randomly divided into six groups: Control group; LPS group; 5 mL/kg DEX + LPS group; 6.6 g/kg QBD extract + LPS group; 17.16 mg/kg PGG + LPS group; 7.26 mg/kg EG + LPS group. The effects of compounds on LPS-induced the number of total cells, neutrophils influx, protein leakage, W/D weight ratio and pulmonary histological changes were examined. The results demonstrated that pretreatment with EG and PGG could notably inhibit lung edema and attenuate the pulmonary histological changes ( Ethyl gallate and pentagalloylglucose of QBD played a protective role in preventing LPS-induced ALI. The results supported further study of EG and PGG as potential candidates for preventing ALI.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to investigate the bioactive constituents of Qingwen Baidu Decoction (QBD) in a rat model of acute lung injury (ALI) induced by lipopolysaccharide (LPS). Our previous studies showed that ethyl gallate (EG) and pentagalloylglucose (PGG) were the active components of QBD for the treatment of ALI.
MATERIALS AND METHODS
METHODS
We isolated two compounds and identified the structures of them by nuclear magnetic resonance and mass spectrometer. Lung injury was induced by intratracheal instillation with LPS (5 mg/kg). Rats were randomly divided into six groups: Control group; LPS group; 5 mL/kg DEX + LPS group; 6.6 g/kg QBD extract + LPS group; 17.16 mg/kg PGG + LPS group; 7.26 mg/kg EG + LPS group. The effects of compounds on LPS-induced the number of total cells, neutrophils influx, protein leakage, W/D weight ratio and pulmonary histological changes were examined.
RESULTS
RESULTS
The results demonstrated that pretreatment with EG and PGG could notably inhibit lung edema and attenuate the pulmonary histological changes (
CONCLUSION
CONCLUSIONS
Ethyl gallate and pentagalloylglucose of QBD played a protective role in preventing LPS-induced ALI. The results supported further study of EG and PGG as potential candidates for preventing ALI.
Identifiants
pubmed: 30587929
doi: 10.2147/DDDT.S186029
pii: dddt-13-071
pmc: PMC6304083
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Hydrolyzable Tannins
0
Lipopolysaccharides
0
lipopolysaccharide, E coli O55-B5
0
qingwen baidu
0
ethyl gallate
235I6UDD3L
pentagalloylglucose
3UI3K8W93I
Gallic Acid
632XD903SP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-77Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Allergy Asthma Proc. 1999 May-Jun;20(3):141-6
pubmed: 10389546
N Engl J Med. 2000 May 4;342(18):1334-49
pubmed: 10793167
Am J Respir Crit Care Med. 2001 May;163(6):1384-8
pubmed: 11371405
Shock. 2002 Apr;17(4):300-3
pubmed: 11954830
Pulm Pharmacol Ther. 2004;17(2):105-10
pubmed: 15123232
Ann Intern Med. 2004 Sep 21;141(6):460-70
pubmed: 15381520
Int Immunopharmacol. 2005 Jun;5(6):1007-17
pubmed: 15829416
Semin Respir Crit Care Med. 2006 Aug;27(4):327-36
pubmed: 16909367
Intensive Care Med. 2007 Mar;33(3):448-53
pubmed: 17221189
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
pubmed: 18621912
J Appl Physiol (1985). 2010 Apr;108(4):845-51
pubmed: 20075264
Toxicol Appl Pharmacol. 2011 Jun 1;253(2):153-60
pubmed: 21473879
Evid Based Complement Alternat Med. 2013;2013:916590
pubmed: 23573157
Biochimie. 2013 Dec;95(12):2404-14
pubmed: 24018486
J Ethnopharmacol. 2014 Apr 11;153(1):197-206
pubmed: 24534526
Molecules. 2017 Apr 26;22(5):null
pubmed: 28445422
J Leukoc Biol. 1988 Nov;44(5):345-52
pubmed: 2846726